Inzoomen: druk op uw toetsenbord op CtrlCommand + +
Uitzoomen: druk op uw toetsenbord op CtrlCommand + -
Gebruik knijpzoomen om eenvoudig in en uit te zoomen

LIPOPROT project

Laatste wijziging: 24 January 2022

Influence of lipoproteins on monocyte function and disease progression in multiple sclerosis

 

Principal Investigator: Prof. Dr. Jerome Hendriks, Researcher: Winde Jorissen

 

The purpose of this study is to determine a possible relationship between lipoprotein levels in the blood and the cerebrospinal fluid (CSF) and the oxidation status of these lipoproteins, the inflammatory phenotype of the monocytes and the disease status (EDSS score) of MS patients. Lipoprotein profiles of plasma and CSF are studied using NMR in collaboration with Dr. Alan Thomas Remaley of the National Institutes of Health (Bethesda, Washington DC, USA). The phenotyping of monocytes is performed using quantitative PCR and validated at protein level using ELISA. The oxidation state of the lipoproteins is determined using TBARS assays and by measuring the formation of conjugated dienes.

 

Changes in lipoprotein levels/subtypes are present in MS. If we know how monocyte phenotype is affected adversely/favorably by certain lipoproteins (or their subtypes/modified forms), we can modulate these lipoprotein levels so that the favorable lipoprotein levels  arise and could result in a more favorable disease course. First of all, these lipoproteins could be used to complement existing therapies for MS (e.g. a diet can be developed that has a positive effect on the levels of favorable lippoteins). Secondly, in future studies, lipoproteins could contribute to the development of new therapies (e.g., compounds such as ApoA-I mimetics, niacin, ...) that have a favorable effect on lipoproteins levels.

 

Publications

  • Jorissen W, Wouters E, Bogie JF, Vanmierlo T, Noben JP, Sviridov D, Hellings N, Somers V, Valcke R, Vanwijmeersch B, Stinissen P, Mulder MT, Remaley AT, Hendriks JJ. Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep. 2017;7:43410.